|
Last
updated February 10, 2005
Saturday, MAY 14
8:00am–11:00am
4102—Imaging
of the Developing Organism: Tools for the Developmental
Biologist
PAS Mini Course
Chair:
Colin K.L. Phoon, New York University School of Medicine,
New York, NY
Rapid advances in developmental genetics over the
past decade have led to the generation of myriad animal
models of abnormal development and the elucidation of many
genes involved in development. Phenotypic analysis has
traditionally been limited to histological or in vitro
techniques. Innovations in sophisticated imaging
modalities now allow investigators to see the results of
genetic manipulation in striking detail, including in vivo
imaging of the embryo, three-dimensional reconstruction of
embryonic structures and functional analysis of the
cardiovascular system. Such imaging tools will prove
invaluable in linking genomic processes with their
phenotypic manifestations. Multi-modality, non-redundant
imaging can help investigators answer key biological
questions. This state of the art mini course is designed
to provide investigators specializing in developmental
processes with an overview of several current innovative
imaging approaches for the study of the embryonic and
early postnatal organism and to stimulate collaboration as
well as advances in phenotypic analyses.
Target Audience: Scientists involved in basic
developmental biology research from various fields,
including cardiology, neurology, cell biology,
developmental biology (patterning, etc.) and genetics.
Introduction: What Can Advanced Imaging Do for the
Developmental Biologist?
Colin
K.L. Phoon, New York University School of Medicine, New
York, NY
In Vivo Ultrasound and MR Microimaging of Mouse Brain
Development
Daniel
H. Turnbull, Skirball Institute of Biomolecular Medicine,
New York University School of Medicine, New York, NY
Optical Projection Tomography: A New Approach for 3D
Microscopy and Gene Expression
James
Sharpe, MRC Human Genetics Unit, Western General Hospital,
Edinburgh, United Kingdom
Quantifying Developmental Dynamics Using DPIV
Jay
R. Hove, Genome Research Institute, University of
Cincinnati, Cincinnati, OH
Break
Dynamic Imaging of Fluid Forces and Heart Motions in
Developing Embryos
Mary
E. Dickinson, California Institute of Technology, Beckman
Institute, Pasadena, CA
Mapping Cardiac Excitation in Embryonic and Adult
Hearts
Gregory
E. Morley, New York University School of Medicine, New
York, NY
Panel Discussion and Question & Answer
11:45am–2:45pm
4503—Neonatal
Follow-Up: A Global Perspective
PAS Mini Course
Chair:
Maureen Hack, Case Western Reserve University, Cleveland,
OH
The increase in survival of extremely immature
infants, together with the institution of randomized
clinical trials to assess the efficacy and safety of the
many technologic and pharmacologic advances in perinatal
care, has led to a renewed interest in current outcomes
and the methodologic issues related to high-risk
follow-up. Questions include the practicality of actual
assessment of children versus the reliability of parental
reports and age of follow-up. Traditional measures of
outcome have included mainly cognitive and neurosensory
function, but there is increasing interest in the overall
functioning of the child, as well as other measures of
health including health status and quality of life. This
session will review epidemiologic principles and state of
the art measures of cognitive and neuropsychologic
assessment, neurologic impairment, including cerebral
palsy, health status, growth and quality of life. The
presentations will be illustrated with examples of recent
outcome studies. Audience participation will be
encouraged.
Target Audience: Scientists and clinicians involved
with clinical care and research pertaining to the results
of neonatal intensive care.
Historical Overview and Introduction
Maureen
Hack, Case Western Reserve University, Cleveland, OH
Epidemiology Principles in Designing, Executing and
Analyzing Newborn Follow-Up Studies
Nigel
Paneth, Michigan State University College of Human
Medicine, East Lansing, MI
Cognitive and Neurophysiologic Outcomes
Glen
Aylward, Southern Illinois University School of Medicine,
Springfield, IL
Cerebral Palsy and Other Neurologic Outcomes
Betty
R. Vohr, Women and Infant's Hospital, Providence, RI
Health Status and Growth
Maureen
Hack, Case Western Reserve University, Cleveland, OH
Issues in Measuring Quality of Life in Children
Saroj
Saigal, McMaster University, Hamilton, Ontario, Canada
Discussion
1:00pm–3:00pm
4650—ADHD:
Issues In Management
PAS Original Science Abstracts -
Platform Session
3:15pm–5:15pm
4802—Traumatic
Brain Injury in Infants and Children
PAS Topic Symposium
Chair:
Patrick M. Kochanek, University of Pittsburgh School of
Medicine and Children's Hospital of Pittsburgh,
Pittsburgh, PA
This program will address state of the art
investigation in the area of traumatic brain injury in
infants and children. Novel studies of the molecular
biology and biochemistry of pediatric traumatic brain
injury will be presented including work studying human
samples (CSF, brain tissue) using molecular tools, such as
proteomics and state of the art magnetic resonance
spectroscopy. Novel therapies will also be addressed,
including an RCT of the application of mild or moderate
therapeutic hypothermia in severe pediatric traumatic
brain injury. Finally, studies addressing the use of serum
biomarkers in the assessment of infants presenting to
emergency departments and outpatient clinics with silent
brain injury from inflicted childhood neurotrauma (child
abuse) will also be presented.
Target Audience: Pediatric practitioners treating
patients with traumatic brain injury; pediatric scientists
carrying out research on patients with traumatic brain
injury or working with models of developmental brain
injury; general practitioners and other clinicians and
investigators who interface on any level with infants who
are victims of inflicted childhood neurotrauma (child
abuse).
Cellular and Molecular Mechanisms of Secondary Injury
in Pediatric Traumatic Brain Injury
Patrick
M. Kochanek, Safar Center for Resuscitation Research,
University of Pittsburgh School of Medicine, Pittsburgh,
PA
Randomized Controlled Trial of Hypothermia in
Pediatric Traumatic Brain Injury
P.
David Adelson, Children's Hospital of Pittsburgh,
Pittsburgh, PA
Spectroscope Applications in Pediatric Traumatic
Brain Injury
Stephen
Ashwal, Loma Linda University School of Medicine, Loma
Linda, CA
A New Approach to the Detection of Inflicted
Childhood Neurotrauma
Rachel
P. Berger, Children's Hospital of Pittsburgh, Pittsburgh,
PA
7:15pm–8:30pm
4991A—Neonatal
Hemodynamics Club
Club
Cerebral Blood
Flow in the Neonate: Autoregulation, Pathophysiology and
Neurodevelopmental Outcome
The Impact of Early Hypotension and Low Systemic
Perfusion on Neurodevelopment in the Preterm Neonate. Do
Our Treatments Help?
David
Osborn, Royal Prince Alfred Hospital, Camperdown,
Australia
Cerebral Autoregulation in the Newborn: Do We Really
Have a Clue?
Adre
J. du Plessis
Contact:
Istvan Seri, M.D., Ph.D.
Children's Hospital at Los Angeles and the Women's and
Children's Hospital at the LAS/USC Medical Center,
University of Southern California
Phone: 323-669-5932
Email: iseri@chla.usc.edu
Sunday, MAY 15
8:00am–10:00am
5104—Whole
Genome Investigation To Identify Susceptibility Genes
PAS Topic Symposium
Chairs:
Diana W. Bianchi, Tufts-New England Medical Center,
Boston, MA and Eric P. Hoffman, Children's National
Medical Center, Washington, DC
With the completion of the human genome, new tools
are now available to identify the genetic determinants for
complex pediatric disorders. This symposium will introduce
these new tools and discuss how they are being applied to
three critically important clinical issues in pediatrics.
First, the use of the HapMap and other recent advances in
whole genome association studies will be reviewed. Second,
the pursuit of susceptibility genes relevant to drug
responsiveness will be presented in the realm of pediatric
organ transplantation. Third, the identification of
susceptibility genes for reading disability will be
discussed.
Finally, the genetics of neurodevelopmental disorders
will be highlighted. The next layer of fundamental
understanding of complex disorders in pediatrics will
depend heavily on such strategies, and this symposium will
relay the matching high levels of excitement and rigor
with which these pursuits should go forth.
Target Audience: Scientists and clinicians involved
in investigations of the genetic basis of pediatric
diseases.
Whole Genome Association Studies for Complex Traits
and Diseases: Role of the HapMap and Other Recent Advances
Joel
N. Hirschhorn, Children's Hospital / Harvard Medical
School, Boston, MA; Broad Institute of MIT and Harvard,
Cambridge, MA
Genetic Contribution to Graft and Patient Outcomes
After Solid Organ Transplantation
Steven
A. Webber, University of Pittsburgh School of Medicine,
Pittsburgh, PA
Identifying Susceptibility Genes for Reading
Disability
Jeffrey
R. Gruen, Yale University School of Medicine, New Haven,
CT
The Genetics of Neurodevelopmental Disorders
Anthony
P. Monaco, University of Oxford, Oxford, England
8:00am–10:00am
5147—Oxidant
Signaling Pathways
PAS Original Science Abstracts -
Poster Symposium
8:00am–11:00am
5200—ADHD
and Other Disruptive Behaviors in Preschool Children:
Challenges in Diagnosis and Treatment
PAS Mini Course
Chair:
Martin T. Stein, University of California San Diego, San
Diego, CA
Pediatricians typically think about ADHD as a
neurobehavioral condition in school-age children and
adolescents. In preschool children, evidenced-based
studies on diagnosis and treatment of ADHD are limited. In
young children, it is especially difficult to distinguish
hyperactivity, impulsive behaviors and inattention from
developmentally normal behavior in this age group. The
session will begin with a discussion about a
developmental–biopsychosocial model for early
identification and treatment of attentional and disruptive
disorders in young children. Recent studies designed to
define an evidenced-based structure for the diagnosis and
treatment of ADHD in young children will be reviewed.
Current knowledge about the effectiveness of behavior
management, parent training and psychopharmacological
treatments in preschool children with ADHD will be
emphasized. The symposium will target the clinical
challenges of working with preschool children who present
with ADHD-like behaviors in pediatric practice.
Target Audience: Clinicians who see preschool
children and teachers of pediatric residents and medical
students; those who do research in developmental and
behavioral pediatrics and pediatric neurology; clinicians
who want to find direction in evaluating and managing
hyperactive, disruptive and impulsive preschool children;
and to clinicians and those who study disruptive behaviors
in preschool children.
ADHD in Preschool Children: Challenges in Definition,
Diagnosis and Treatment
Martin
T. Stein, University of California San Diego, San Diego,
CA
Developmental–Biopsychosocial Model for Early
Identification and Comprehensive Treatment of Attentional
and Disruptive Disorders in Young Children
Stanley
I. Greenspan, George Washington University School of
Medicine, Washington, DC
Diagnostic Strategies for ADHD in Preschool Children
Helen
Link Egger, Duke University Medical Center, Durham, NC
Treatment of Disruptive Behaviors in Preschool
Children
Chris
K. Varley, University of Washington Medical Center,
Children's Hospital and Regional Medical Center, Seattle,
WA
The Preschool ADHD Treatment Study (PATS Study)
Larry
L. Greenhill, New York State Psychiatric Institute, New
York, NY
Managing Disruptive Preschool Children with ADHD in a
Pediatric Office
Suzanne
Dixon, University of Washington, University of California
San Diego, Emeritus
Discussion
Sunday, MAY 15
12:00pm–1:30pm
5494A—Perinatal
Brain Club
Club
Impact of Neonatal Seizures on the
Developing Brain
Basic Mechanisms of Epileptogenesis in the Developing
Brain
Brenda
Porter, Children's Hospital of Philadelphia, Philadelphia,
PA
Imaging and Neonatal Seizures—Can We Predict
Outcome
Steven
P. Miller, University of California at San Francisco, San
Francisco, CA
The Role of aEEG in the Detection and Monitoring of
Neonatal Seizures
Linda
DeVries, Wilhelmina Children's Hospital, Utrecht, The
Netherlands
Contact:
Jeff Perlman, M.D.
Weill Medical College of Cornell University
Phone: 212-746-3530
Email: jmp2007@med.cornell.edu
2:00pm–4:00pm
5535—Neonatal
Epidemiology and Follow-up
PAS Original Science Abstracts -
Platform Session
2:00pm–4:00pm
5537—Neurology/Neonatal
Neurology
PAS Original Science Abstracts -
Platform Session
2:00pm–5:00pm
5561—Pediatric
Neuropharmacology—Current Controversies
PAS Mini Course
Chair:
Faye Silverstein, University of Michigan, Ann Arbor, MI
This mini course will highlight issues of interest to
many pediatricians. Neuroactive drugs are used to treat a
wide range of neurological and behavioral disorders in
children and adolescents. Often, these drugs have not been
systematically evaluated in this age group, and the issue
of “off-label” use of neuroactive drugs has recently
received considerable national attention.
We have recruited five experts in pediatric
therapeutics for this mini course. Four will discuss
treatment issues, and the fifth will discuss ethical
issues that must be considered in pediatric drug testing.
Graham Emslie will discuss the safety and efficacy of
selective serotonin release inhibitors (SSRIs) in children
and adolescents with depression and related disorders. The
controversies regarding the use of these agents in the
pediatric age group have raised important questions for
all pediatricians. He will also highlight important
questions for future research to improve clinical outcomes
of children with psychological disorders.
James McCracken will provide his perspective on the
use of second generation antipsychotics in children and
adolescents. These drugs are widely used to treat a broad
range of behavioral disorders. He will review current
information about the efficacy and tolerability of these
drugs and suggest guidelines for clinical monitoring.
Carter Snead will provide his perspective on the
roles of the new generation of anti-convulsant drugs
(introduced over the past 10 years) in the treatment of
childhood epilepsy. He will discuss some of the drugs that
have already gained widespread usage in children and
discuss their potential risks and benefits.
Judith Owens will discuss current approaches to drug
therapy of pediatric sleep disorders. As new drug
therapies are introduced, both to induce sleep and to
sustain wakefulness, it is likely that their use will
extend to children and adolescents. The diagnosis of sleep
disorders is rapidly increasing in children, and Dr. Owens
will discuss major diagnostic and therapeutic issues.
Joel Frader will discuss ethical issues in pediatric
drug testing. His topics will include: who should give
“consent” for study participation, the circumstances
permitting placebo controls, implications of FDA and/or
NIH incentives/mandates for pediatric testing, conflicts
between care giving and researcher roles, obligations to
provide study results to participants and special
considerations for phase I testing.
Target Audience: Broad range of clinicians who treat
children with neurological and psychological disorders.
Introduction
Faye
S. Silverstein, University of Michigan, Ann Arbor, MI
SSRIs in Pediatrics: What Do We Really Know?
Graham
Emslie, University of Texas–Southwestern Medical Center,
Dallas, TX
Promises and Pitfalls of Newer Antipsychotics in
Children and Adolescents
James
McCracken, UCLA Neuropsychiatric Institute, Los Angeles,
CA
New Anticonvulsants—Roles in Treatment of Childhood
Epilepsy
O.
Carter Snead, The Hospital for Sick Children, University
of Toronto, Toronto, Canada
Drug Therapy of Pediatric Sleep Disorders
Judith
A. Owens, Brown University, Providence, RI
Pediatric Drug Testing: Ethical Considerations
Joel
E. Frader, Children's Memorial Hospital, Chicago, IL
Discussion
6:15pm–9:00pm
5880A—Society
for Developmental Pediatrics
Club
Research into Neurodevelopmental
Disabilities: Past, Present and Future
Update on Neurodevelopmental Disabilities Training
Bruce
K. Shapiro
Research into Neurodevelopmental Disabilities: Past,
Present and Future
Mark
L. Batshaw
Update on the Relationship of the SDP and the Child
Neurology Society
Peter
A. Blasco, Associate Professor of Pediatrics, Oregon
Health & Science University
Contact:
Peter Blasco, M.D.
Lend Training Program and CDRC, Portland, OR
Phone: 503-494-2756
Email: blascop@ohsu.edu
Monday, MAY 16
8:00am–10:00am
6131—Brain
Metabolism and Injury
PAS Original Science Abstracts -
Platform Session
8:00am–10:00am
6132—Clinical
Trials in Perinatal and Neonatal Medicine I
PAS Original Science Abstracts -
Platform Session
8:00am–10:00am
6133—Development
Biology
PAS Original Science Abstracts -
Platform Session
8:00am–10:00am
6139—Neonatal
Outcomes: Impact of Health Services Utilization and
Socioeconomics
PAS Original Science Abstracts -
Platform Session
8:00am–10:00am
6141—Neurodevelopmental
Disabilities
PAS Original Science Abstracts -
Poster Symposium
10:15am–12:15pm
6351—Behavioral–Developmental
Pediatrics
PAS Original Science Abstracts -
Platform Session
3:00pm–5:00pm
6702—Neonatal
Neuropharmacology in 2005
PAS Topic Symposium
Chair:
Faye Silverstein, University of Michigan, Ann Arbor, MI
A critical priority for neonatal medicine is the
challenge of understanding the impact of diverse forms of
therapy on brain development. It remains extremely
challenging to design feasible studies to address this
theme. In infants with underlying neurological disorders
it is particularly difficult to distinguish whether
long-term adverse effects reflect underlying
neuropathology or deleterious effects of a specific
therapy. The three speakers will provide an overview of
current and future approaches to treat the major
neurological disorders that affect neonates and how the
risks and benefits of treatment can be dissected.
Donna Ferriero will discuss current strategies for
selection of neonates for neuroprotection therapy and new
approaches for the development of more effective
neuroprotection interventions. She will discuss mechanisms
of brain injury and repair that are unique to the
developing brain. She will highlight the scientific
rationale for development of combination therapies that
may be most successful in protecting the injured neonatal
brain.
Scott Rivkees will highlight new information about
adenosine pharmacology in the neonatal brain. Caffeine is
a multifunctional drug that blocks adenosine action. High
doses of caffeine exert adverse effects on the developing
brain; however, recent evidence suggests that blocking
adenosine action may reduce certain forms of brain injury
in experimental models. His talk will address influences
of caffeine action and adenosine blockade during
development.
Faye Silverstein will discuss information about the
current treatment of neonatal seizures and strategies for
improving diagnosis and treatment. Her talk will highlight
some of the major unanswered questions about diagnosis and
treatment of neonatal seizures. She will also discuss the
implications of recent basic science findings regarding
risks of anti-convulsant therapy in the developing brain.
Target Audience: Clinicians involved in the treatment
of neonates with neurological disorders and scientists
interested in mechanisms of neonatal brain injury and
repair.
Introduction
Faye
S. Silverstein, University of Michigan, Ann Arbor, MI
Neonatal Neuroprotection: Cocktails and Ice
Donna
M. Ferriero, University of California, San Francisco, CA
Effects of Caffeine and Other Adenosine Antagonists
on Brain Development
Scott
A. Rivkees, Yale School of Medicine, New Haven, CT
Neonatal Seizures: How Can Treatment Be Improved?
Faye
S. Silverstein, University of Michigan, Ann Arbor, MI
Discussion
3:00pm–5:00pm
6731—Management
and Outcomes of Very Low Birth Weight Infants
PAS Original Science Abstracts -
Platform Session
3:00pm–5:00pm
6733—Neonatal
Neurology—Neuroinflammation
PAS Original Science Abstracts -
Poster Symposium
3:00pm–5:00pm
6735—Pharmacology
PAS Original Science Abstracts -
Platform Session
5:15pm–6:45pm
Poster
Session III
PAS Original Science Abstracts -
Poster Session
Developmental Biology:
6850—Brain
Neonatal Neurology:
6880—Mechanisms of Disease
Tuesday, MAY 17
8:00am–10:00am
7152—Clinical
Trials in Perinatal and Neonatal Medicine II
PAS Original Science Abstracts -
Platform Session
8:00am–10:00am
7159—Neonatal
Neurology—Experimental Models
PAS Original Science Abstracts -
Poster Symposium
12:00pm–1:30pm
Poster
Session IV
PAS
Original Science Abstracts - Poster Session
Neonatology:
7435—CNS
Neonatal Neurology:
7440—Neonatal Neurology
7441—Seizures
7442—MRI
Neurology:
7450—Clinical
|
